Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Trial details
- Registry ID
- NCT01838395
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Cytarabine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsNCT01838395 | BLRX | Phase 2 | Completed | 2016-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |